No Data
No Data
Allogene Therapeutics To Present Updated Data From Completed Phase 1 TRAVERSE Trial Of ALLO-316 In Oral Presentation At 2025 ASCO
Analysts' Top Healthcare Picks: Allogene Therapeutics (ALLO), Immunovant (IMVT)
William Blair Maintains Allogene Therapeutics(ALLO.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Allogene Therapeutics (ALLO)
Allogene Granted 3 U.S. FDA Fast Track Designations For ALLO-329 For The Treatment Of Lupus, Myositis And Scleroderma
Express News | Allogene Therapeutics Inc: Expects to Initiate Phase 1 Resolution Basket Trial in Mid-2025